Dexcom Q4 profit beats estimates

DexCom

12/02/2026 21:12

Overview

Biosensing tech firm's Q4 revenue grew 13% yr/yr

Adjusted EPS for Q4 beat analyst expectations

Company launched Dexcom G7 CGM system and expanded access in Québec

Outlook

Dexcom expects 2026 revenue between $5.16 bln and $5.25 bln

Company sees 2026 non-GAAP gross profit margin at 63-64%

Dexcom forecasts 2026 adjusted EBITDA margin of 30-31%

Result Drivers

DEXCOM G7 LAUNCH - Co launched Dexcom G7 15 Day CGM system in the U.S., contributing to revenue growth

FDA CLEARANCE - Co received FDA clearance for Dexcom Smart Basal, enhancing product offerings

QUÉBEC EXPANSION - Expanded access to Dexcom CGM in Québec under RAMQ, increasing market penetration

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Beat
$0.68
$0.65 (23 Analysts)
Q4 Adjusted Net Income
Beat
$265.10 mln
$259.79 mln (17 Analysts)
Q4 Adjusted Operating Income
Beat
$331.50 mln
$307.38 mln (21 Analysts)
Q4 Adjusted Gross Profit
$799.80 mln
Q4 Gross Profit
$792.70 mln
Q4 Operating Income
$323 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 26 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Dexcom Inc is $84.41, about 23.9% above its February 11 closing price of $68.15

The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release: ID:nBw26wZfxa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)